Valemetostat for solid tumors with SWI/SNF gene changes
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new drug, valemetostat, for solid tumors that have specific genetic changes (like loss of SMARCB1, SMARCA4, or ARID1A). It is for people whose cancer has continued to grow despite other treatments. The study will see if valemetostat can help shrink or slow tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid tumor (like kidney, ovarian, or endometrial cancer) that has spread or come back, and standard treatments are no longer working.
- A genetic test shows your tumor has lost a specific gene from the SWI/SNF group (like SMARCB1, SMARCA4, ARID1A, PBRM1, BAP1, or others).
- You have an archived tissue sample or are willing to have a new biopsy to confirm the gene loss.
- You are 18 or older and able to undergo scans (CT or MRI) to measure your tumor.
- Your overall health (ECOG score 0 or 1) allows you to be up and about, with expected survival of at least 12 weeks.
- You have adequate blood counts, liver, and kidney function based on lab tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs (valemetostat and darolutamide) for men with metastatic castration-resistant prostate cancer that has worsened after prior treatment. The goal is to see if the combination can slow cancer growth.
This trial tests a new combination of two drugs (valemetostat and atezolizumab) for people with extensive-stage small cell lung cancer who have already responded to initial chemo-immunotherapy. The goal is to see if adding valemetostat can keep the cancer from growing longer.
This study tests an experimental drug called VVD-159642 in people with advanced solid tumors that have specific genetic changes (RAS or EGFR alterations, or HER2 overexpression). The goal is to see if the drug is safe and tolerable.
This trial tests a combination of three drugs—valemetostat, atezolizumab, and bevacizumab—for people with advanced liver cancer (HCC) who have not had systemic treatment before. The goal is to see if this combination can shrink tumors or slow disease progression.
This Phase 1 trial tests how safe and effective two anti-cancer drugs (peposertib and tuvusertib) are for advanced solid tumors. It focuses on cancers with specific DNA repair and cell-growth gene changes, aiming to shrink tumors and improve outcomes when standard treatments have stopped working.
This trial tests a new drug, Navlimetostat (BMS-986504), for people with advanced solid tumors that have a specific genetic change called MTAP deletion or loss. It looks at safety, side effects, and how the drug works in the body.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.